Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant비활성화 백신을 사용한 이종 면역화 후 mRNA-부스터는 SARS-CoV-2 오미크론 변이체에 대한 강력한 면역을 유도합니다Article Published on 2022-05-132022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] boost booster Cell Cellular immune response dose ectodomain Efficacy elicit Heterologous heterologous immunization homologous humoral Humoral and cellular immune responses IgG antibodies IgG antibody immune responses Immunity Inactivated vaccine Inactivated Vaccines increase individual Infection memory B memory B cell mRNA vaccine omicron Omicron variant Omicron variants plasma raised RBD receiving Receptor-binding domain SARS-CoV-2 significantly significantly increased specific antibodies specific antibody T cell T cell response the receptor-binding domain vaccination Vaccination strategies Vaccine vaccine efficacy variant variants variants of concern virus Virus neutralization [DOI] 10.1038/s41467-022-30340-5 PMC 바로가기 [Article Type] Article
Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice마우스에서 명반 면역증강제가 첨가된 비활성화 SARS-CoV-2 백신의 2~3회 투여에 의해 유도된 면역 반응의 비교Article Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adjusting alum alum-adjuvanted inactivated SARS-CoV-2 vaccine Analysis antibody BNT162b2 boost CD4+ CD8+ Cell-mediated immunity cellular cellular immunity clinical trials coronavirus dose doses Heterologous homologous humoral Humoral response humoral responses IgG responses immune response immune responses immunization immunization schedule immunization schedules inactivated memory mice offer respiratory response SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose severe acute respiratory syndrome Coronavirus significantly spike-specific cellular immunity spike-specific IgG T cell T cell response tested Th2 Vaccine development variant [DOI] 10.1002/jmv.27637 PMC 바로가기 [Article Type] Article
Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England영국에서 Pfizer 및 AstraZeneca 백신을 사용한 이종 프라임-부스트 COVID-19 백신 접종 일정에 따른 면역 반응에 대한 실제 데이터Article Published on 2022-05-012022-09-12 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adults anti-SARS-CoV-2 AstraZeneca blood sample BNT162b2 ChAdOx1 nCoV-19 Cohort Concentration COVID-19 COVID-19 vaccination declined dose doses eligible England geometric mean geometric mean ratio GMC GMR group Heterologous heterologous prime-boost heterologous schedule homologous IgG antibody immune response immunogenic individual lowest mRNA vaccine National Pfizer Pfizer-BioNTech provided receiving remained SARS-CoV-2 second dose serious adverse reaction significantly higher significantly lower vaccination Vaccine [DOI] 10.1016/j.jinf.2022.01.038 PMC 바로가기 [Article Type] Article
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques원숭이의 SARS-CoV-2 오미크론 변종에 대한 백신 보호Article Published on 2022-04-282022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus antibody Antibody titer Antibody titers B.1.1.529 BNT162b2 BNT162b2 vaccine Bronchoalveolar lavage CD8+ T cell Cellular immune response contribute correlated cynomolgus macaques demonstrated Efficacy heterologous prime-boost High-dose homologous humoral immune responses macaque macaque. moderate mRNA mRNA-based mutated nasal swabs neutralizing antibody titers omicron populations question raised regimen respiratory response robust SARS-CoV-2 SARS-CoV-2 variant Spread T cell T cell responses the SARS-CoV-2 These data undetectable upper respiratory tract Vaccine Vaccines variant virus [DOI] 10.1016/j.cell.2022.03.024 PMC 바로가기 [Article Type] Article
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung OrganoidshiPSC에서 파생된 폐 오르가노이드에서 SARS-CoV-2에 대한 두 가지 다른 치료 접근 방식Article Published on 2022-04-052022-09-11 Journal: Cells [Category] COVID19(2023년), SARS, 바이오마커, 변종, [키워드] ACE2 airways alveolar approach approaches AT2 candidate Cell complex COVID-19 COVID-19 treatment develop dipeptidyl peptidase Dipeptidyl peptidase-4 distal DPP4 drugs Efficacy Efficiency evaluate Evidence Express expression of gene health emergency hiPSCs hLORGs homologous host cells human cells implicated in vitro in vivo Infection Inflammatory response Innate immunity lung modulation monoclonal Neutralizing neutralizing antibody neutralizing monoclonal antibody organ Organoid peptide pluripotent stem cell Protein proximal pseudovirus receptor receptors reducing reduction SARS-CoV-2 SARS-CoV-2 S SARS-CoV2 SARS-CoV2 pseudovirus spike Spike protein stem cells Structure synthetic peptide tested tetravalent therapeutic These data treated Treatment variant Viral viral entry were infected [DOI] 10.3390/cells11071235 PMC 바로가기 [Article Type] Article
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination동종 ChAdOx1-nCoV-19 또는 동종 mRNA-1273 백신과 비교한 이종 ChAdOx1-nCoV-19/mRNA-1273 백신의 면역 반응 및 안전성Article Published on 2022-04-012022-09-11 Journal: Journal of the Formosan Medical Association = Taiw [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adenovirus Adenovirus-vector vaccine Adverse adverse event adverse events AEs Alpha anti-SARS-CoV-2 IgG AstraZeneca B.1.1.7 B.1.617.2 ChAdOx1 ChAdOx1-nCoV-19 comparable coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 vaccines Efficacy enrolled event female four groups group Heterologous heterologous prime-boost homologous homologous or heterologous IgG titers immune response less median age messenger Messenger RNA vaccine Mild Moderna MOST mRNA mRNA-1273 Neutralizing antibody response Neutralizing antibody titer neutralizing antibody titers participant Primary outcome provided recruited RNA SARS-CoV-2 second dose serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) significantly higher Support vaccination vaccination schedule Vaccines variant Volunteer was done were recorded [DOI] 10.1016/j.jfma.2022.02.020 PMC 바로가기 [Article Type] Article
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults – VISION Network, 10 States, December 2021-March 2022Ad.26.COV2.S(Janssen [Johnson & Johnson]) 백신 1회 투여 후 동종 및 이종 COVID-19 추가 용량의 효과 COVID-19 관련 응급실 및 성인의 긴급 치료 만남 및 입원에 대한 백신 용량 - VISION Network, 10 미국, 2021년 12월-2022년 3월Article Published on 2022-04-012022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] addition Adenovirus Against booster booster dose booster vaccination Care CDC circulating clinical trial comparable COVID-19 COVID-19 vaccine Department dose doses Effectiveness eligible Emergency encounter examined Guillain-barrè syndrome Heterologous heterologous mRNA vaccine homologous Hospitalization hospitalizations janssen laboratory-confirmed mRNA mRNA vaccine mRNA vaccines network Neutralizing antibody response omicron predominant provided receipt receive risk Serious Adverse Event Serious Adverse Events syndrome thrombocytopenia thrombosis time interval vaccination Vaccination strategy Vaccine vaccine dose variant [DOI] 10.15585/mmwr.mm7113e2 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemicCOVID-19 전염병의 통제를 개선하기 위한 SARS-CoV-2 백신 연구 및 예방 접종 전략Review Published on 2022-04-012022-09-11 Journal: Frontiers of medicine [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 booster dose Chinese Combination coronavirus 2 coronavirus disease Coverage COVID-19 COVID-19 pandemic develop diagnostics drugs effective vaccine Effective vaccines effort facilitated genomic sequence herd immunity Herd immunity threshold homologous homologous or heterologous immune protection immunization strategies immunization strategy immunize multidimensional Older pandemic Pandemics population immunity regulatory agencies regulatory agency Research SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants Scientific community Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus vaccination Vaccination strategies Vaccine vaccine immunity Vaccines virus variant virus variants [DOI] 10.1007/s11684-021-0913-y PMC 바로가기 [Article Type] Review
Comparative Analysis of SARS-CoV-2 Variants of Concern, Including Omicron, Highlights Their Common and Distinctive Amino Acid Substitution Patterns, Especially at the Spike ORF오미크론을 포함한 우려되는 SARS-CoV-2 변이체의 비교 분석은 특히 스파이크 ORF에서 공통적이고 독특한 아미노산 치환 패턴을 강조합니다Comparative Study Published on 2022-03-292022-09-11 Journal: Viruses [Category] SARS, 변종, [키워드] acid Alpha Amino acid amino acid substitution amino acid substitutions Analysis Beta common Comparative concern COVID-19 Delta dN/dS Evolution Gamma highest homologous hotspot human host Hypothesis Including introduced investigated Lambda Lineage lineages mutated mutations omicron ORF phylogenetic distribution Point mutation Positive selection RBD Receptor binding domain Recombination recurrent mutations residue Sarbecoviruses SARS-CoV-2 significantly higher spike Substitution the Spike vaccination variant variants variants of concern was performed [DOI] 10.3390/v14040707 PMC 바로가기 [Article Type] Comparative Study
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2동종 2회 용량 ChAdOx1 대 ChAdOx1 및 BNT162b2를 사용한 이종 백신의 비교 효과 및 안전성Article Published on 2022-03-232022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, [키워드] 95% confidence interval age Analysis BNT162b2 ChAdOx1 Cohort cohort analysis Comparative COVID-19 Delta dose Effectiveness first dose followed by generate group hazard ratio Heterologous homologous immune response Infection Linked data MOST negative control occurred outcome outcomes Phase 2 predominant randomised receiving resulting Safe SARS-CoV-2 variant second dose Sex Spain suggested These data Trial trials two group two groups vaccination vaccination schedule [DOI] 10.1038/s41467-022-29301-9 PMC 바로가기 [Article Type] Article